Menu
ncarol.com
  • Home
  • Business
  • Financial
  • Yacht Buyer
  • Stocks
  • Finance
  • Banking
  • Nyse
  • Loans
ncarol.com

Juventix Regenerative Medical PRP Highlighted in University-Published Research Study
ncarol.com/10280466

Trending...
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
  • Still Using Ice? FrostSkin Reinvents Hydration
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
Laboratory Testing for Product Validation BSR Labs Juventix PRP Study Table Juventix Packaging With Tubes Juventix Regenerative Medical, LLC
TAMPA, Fla. - ncarol.com -- Juventix Regenerative Medical, a leader in regenerative medicine solutions, proudly announces that its Platelet-Rich Plasma (PRP) technology has been featured in a groundbreaking university-published research study. The study, titled "Platelet-Rich Plasma for Rheumatoid Arthritis: A Case Series", published in the peer-reviewed journal Cureus, underscores the efficacy of Juventix PRP in managing rheumatoid arthritis, showcasing its transformative potential in clinical applications.

The study explores the use of PRP to address inflammation and improve outcomes in rheumatoid arthritis patients, with findings demonstrating measurable benefits attributed to Juventix PRP's advanced process. The research highlights the role of PRP in promoting tissue repair and reducing joint pain, offering a promising non-surgical alternative for patients seeking regenerative therapies.

Scientific Validation Backed by Laboratory Studies
Juventix PRP's inclusion in this research aligns with findings from extensive laboratory evaluations conducted by BioSciences Research Associates (2020) and Biofyl Scientific Research (2023). Key results include:
  • 84% platelet recovery, significantly enhancing platelet-derived growth factor (PDGF) concentrations.
  • 10x increase in PDGF levels, with treated PRP reaching 10,844 pg/mL compared to 1,536 pg/mL in untreated samples.
  • Minimal contamination of red and white blood cells, ensuring safety and reducing inflammatory risks.
  • Optimized pH of 7.5, creating an ideal environment for platelet activation and growth factor release.
  • Innovative activation methods, including photoactivation and bio-incubation, transforming PRP into PRF for versatile clinical applications.
"The inclusion of Juventix PRP in a peer-reviewed study underscores our commitment to delivering scientifically validated, high-quality regenerative solutions," said Lance Liberti, CEO of Juventix Regenerative Medical. "Our focus on innovation ensures practitioners can trust Juventix PRP for consistent, superior patient outcomes."

More on ncarol.com
  • $36 Million LOI to Acquire High Value Assets from Vivakor Inc in Oklahoma's STACK Play — Building Cash Flow and Scalable Power Infrastructure; $OLOX
  • Kobie Wins for AI Innovations in the 2026 Stevie® Awards for Sales & Customer Service
  • Berman | Sobin | Gross LLP Celebrates 35 Years of Advocating for Maryland's Injured Workers and Families
  • Art of Whiskey Hosts 3rd Annual San Francisco Tasting Experience During Super Bowl Week
  • PADT Earns Prestigious 2025 Americas Customer Loyalty Award from Ansys, Part of Synopsys

Special Offer for Medical Practitioners
To introduce clinicians to its cutting-edge PRP systems, Juventix is offering a sample PRP kit for only $20. This limited-time opportunity enables practitioners to experience the proven quality of Juventix PRP firsthand.
• Email: hello@juventix.com with the subject line "SAMPLE"
• Visit: https://juventix.com/sample-page/

About Juventix Regenerative Medical, LLC
Founded in 2017 by Lance Liberti, Juventix Regenerative Medical has been a pioneer in non-surgical regenerative solutions, including FDA-cleared PRP kits. The company offers comprehensive products such as centrifuges, LED activators, and bio-incubators to support superior PRP preparation. Juventix also collaborates with prestigious organizations, including the University of South Florida (USF) Health Center for Advanced Medical Learning and Simulation (CAMLS), to host advanced clinical training symposiums.

For more information, visit www.Juventix.com or contact:
📞 (866) 693-4777

More on ncarol.com
  • Florida Keys Visitors Can Save 15 Percent With KeysCaribbean's Advanced Booking Discount
  • Sleep Basil Unveils Revamped Natural Latex Mattress Collection Page for Cooler, Cleaner, Better-Aligned Sleep
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
  • DASH Carolina RDU Sets the Pace in 2025 with Record-Breaking Sales and Team Excellence
  • Wespor Business Launches AI Voice and Chat Agents to Help Triangle Small Businesses Capture Missed Leads

✉️ Email:
hello@juventix.com
Restore, Revive, Regenerate – Juventix Regenerative Medical.

Media Contact
Lance Liberti
***@juventix.com
866-693-4777


Source: Juventix Regenerative Medical, LLC

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Slotozilla Reports Strong Q4 Growth and Sigma Rome Success
  • "Lights Off" and Laughs On: Joseph Neibich Twists Horror Tropes in Hilariously Demonic Fashion
  • Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
  • Beethoven: Music of Revolution and Triumph - Eroica
  • Amy Turner Receives 2025 ENPY Partnership Builder Award from The Community Foundation
  • The "Human Bridge": Why Leading with Tools is Failing Our Children
  • Hubble Tension Solved? Study finds evidence of an 'Invisible Bias' in How We Measure the Universe
  • Boonuspart.ee Acquires Kasiino-boonus.ee to Strengthen Its Position in the Estonian iGaming Market
  • Vines of Napa Launches Partnership Program to Bolster Local Tourism and Economic Growth
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
  • Angels Of Dirt Premieres on Youtube, Announces Paige Keck Helmet Sponsorship for 2026 Season
  • Still Using Ice? FrostSkin Reinvents Hydration
  • Patron Saints Of Music Names Allie Moskovits Head Of Sync & Business Development
  • Dave Aronberg Named 2026 John C. Randolph Award Recipient by Palm Beach Fellowship of Christians & Jews
  • General Relativity Challenged by New Tension Discovered in Dark Siren Cosmology
  • Unseasonable Warmth Triggers Early Pest Season Along I-5 Corridor
  • Bug Busters Expands Service Footprint With New Carrollton, Georgia Branch
  • Why KULR Could Be a Quiet Enabler of Space-Based Solar Power (SBSP) Over The Long Term: KULR Technology Group, Inc. (NY SE American: KULR)
  • Why Finland Had No Choice But to Legalize Online Gambling
  • High-Margin Energy & Digital Infrastructure Platform Created after Merger with Established BlockFuel Energy, Innovation Beverage Group (NAS DAQ: IBG)
_catLbl0 _catLbl1

Popular on ncarol.com

  • Crossroads4Hope Welcomes New Trustees to Board of Directors as Organization Enters 25th Year of Caring - 119
  • Desert Mountain Club Earns Prestigious Blue Zones Approved™ Triple Designation, a New Standard for Well-Being in a Luxury Lifestyle Community
  • $80 Million Revenue Backlog for AI Cybersecurity Company Building the Future of Integrated Cybersecurity and Public Safety: $CYCU
  • Finland's €1.3 Billion Digital Gambling Market Faces Regulatory Tug-of-War as Player Protection Debate Intensifies
  • Impact Futures Group expands through acquisition of specialist healthcare sector training provider Caring for Care
  • New Medium Article Explores Why Emotional Conversations Fail and What Most People Don't Understand About Connection
  • Does EMDR Really Work? New Article Explores How Trauma Gets Stuck in the Brain and How Healing Begins
  • Postmortem Pathology Expands to Phoenix: Bringing Families Answers During Their Most Difficult Moments
  • UK Financial Ltd Advances Compliance Strategy With January 30th CATEX Exchange Listing Of Maya Preferred PRA Preferred Class Regulated Security Token
  • Blasting Off with Space Sector Companies: Artemis II Manned Moon Mission is Set to Launch: Could $ASTI be on the Same Rocket Ride as $ASTS & $LUNR?

Similar on ncarol.com

  • Revolutionary Data Solution Transforms Health Insurance Underwriting Accuracy
  • Sleep Basil Unveils Revamped Natural Latex Mattress Collection Page for Cooler, Cleaner, Better-Aligned Sleep
  • Conexwest Delivers Custom Shipping Container MRI Lab, Saving California Hospital an Estimated $9 Million in Renovation Costs
  • FDA Meeting Indicates a pivotal development that could redefine the treatment landscape for suicidal depression via NRx Pharmaceuticals: $NRXP
  • CCHR: Decades of Warnings, Persistent Inaction; Studies Raise New Alarms on Psychiatric Drug Safety
  • Arbutus Medical Raises C$9.3M to Accelerate Growth of Surgical Workflow Solutions Outside the OR
  • Cold. Clean. Anywhere. Meet FrostSkin
  • Families Gain Clarity: Postmortem Pathology Expands Private Autopsy Services in St. Louis
  • Amy Turner Receives 2025 ENPY Partnership Builder Award from The Community Foundation
  • Hubble Tension Solved? Study finds evidence of an 'Invisible Bias' in How We Measure the Universe
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute